Fibrous sheath interacting protein 1 overexpression is associated with unfavorable prognosis in bladder cancer: A potential therapeutic target

OncoTargets and TherapySun M, et al. | August 17, 2017


The clinical significance of fibrous sheath interacting protein 1 (FSIP1) in bladder cancer, and its potential relevance to the survival of patients with bladder cancer had been examined by this study. In these patients, findings outlined an association of FSIP1 overexpression with unfavorable prognosis. These outcomes indicated that FSIP1 represented a potential therapeutic or predictive target for bladder cancer.

  • The clinicians gathered 225 surgical excised-bladder cancer tissues from the patients with the follow-up data >5 years, and they assayed FSIP1 expressions by using immunohistochemistry.
  • Quantitative real-time polymerase chain reaction (PCR) and Western blotting analysis measured the messenger RNA (mRNA) and/or protein levels of FSIP1 in fresh bladder tumor tissues as well as bladder cancer cell lines.
  • Analysis was done for the correlation of FSIP1 expression with clinicopathological parameters.
  • Moreover, Western blotting analysis revealed that FSIP1 protein was detected in 94.1% (16/17) of bladder tumor specimens and in all three bladder cancer cell lines (5637, BIU-87, and T24 in particular), with significantly higher expression than those of their controls.
  • As compared to normal adjacent tissues, an increased FSIP1 mRNA expression level was observed in bladder cancer tissues.
  • A good correlation was found between FSIP1 overexpression and tumor stage as well as lymph node metastasis.
  • In addition, positive FSIP1 expression was independently associated with an unfavorable overall and disease-free survival by multivariate Cox regression (P=0.037 and 0.019, respectively).

Read the full article on OncoTargets and Therapy